IDIA — Idorsia Share News
0.000.00%
Last trade - 00:00- CH₣1.13bn
- CH₣2.28bn
- CH₣220.58m
Brief: Idorsia 9M EBIT CHF -99 Million
Swiss stocks - Factors to watch on October 29
Brief: Idorsia And SPV Investors Partner To Unlock Blockbuster Potential Of Tryvio/Jeraygo
Development And Commercialization Agreement With Nxera
Brief: Idorsia Seeks US Label Update For Quviviq
Idorsia jumps after advancing study of autism spectrum disorder drug daridorexant
Brief: Idorsia Says To Advance Development In Autism Spectrum Disorder
Brief: Idorsia Presents Results With Daridorexant In Children And Adolescents With Insomnia
Brief: Idorsia Says Aprocitentan Cuts Blood Pressure Across Cardiometabolic Disease Spectrum
Brief: Idorsia Announces Positive Phase 3 Precision Study Findings In Obesity-Associated Resistant Hypertension And Ckm Continuum
Swiss stocks - Factors to watch on July 13
Brief: Idorsia Appoints Roland Wandeler As CEO
Brief: Idorsia Enters Senior Secured Term Loan Of Up To CHF 250 Million
Swiss stocks - Factors to watch on May 15
Switzerland's Idorsia posts Q1 loss as high QUVIVIQ sales more than offset by costs, lack of one-time gain
Brief: Idorsia Financial Guidance For 2026 Unchanged
Swiss stocks - Factors to watch on April 28
Brief: Idorsia Reports Daridorexant Results In A Phase 2 Study In Children With Insomnia Disorder
Brief: Idorsia Says CEO Srishti Will Step Down From Her Role